Zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy, defined as an albumin-corrected calcium (cCa) of greater than or equal to 12 mg/dL. The treatment is also indicated for patients with multiple myeloma and bone metastases from solid tumors, provided the prostate cancer has progressed after hormonal therapy.
Mechanism of Action and Clinical Results
The mechanism of action involves inhibiting bone resorption by osteoclasts, inducing their apoptosis, and blocking the resorption of mineralized bone and cartilage. Clinical studies demonstrated that a single-dose intravenous infusion of 4 mg of **zoledronic acid injection** results in decreases in serum calcium and phosphorus, and increases in urinary calcium and phosphorus excretion in patients with hypercalcemia of malignancy. The primary efficacy variable was the proportion of patients achieving a corrected serum calcium (CSC) of less than or equal to 10.8 mg/dL within 10 days. In pooled studies, 88% of patients achieved normalization of CSC with 4 mg zoledronic acid injection compared to 70% with pamidronate 90 mg (P=0.002).
Patient Demographics and Dosage
The incidence of renal toxicity and renal failure was shown to be reduced when zoledronic acid injection 4 mg is given as a 15-minute intravenous infusion. The most common tumor types in clinical studies were lung, breast, head and neck, and renal. The mean age of the study population was 59 years; 81% were Caucasian, 15% were Black, and 4% were of other races. Sixty percent (60%) of the patients were male. The maximum recommended dose for hypercalcemia of malignancy is 4 mg as a single-use intravenous infusion over no less than 15 minutes. Retreatment is given after a minimum of 7 days. Dose adjustments are not necessary in treating patients for hypercalcemia of malignancy presenting with mild-to-moderate renal impairment prior to initiation of treatment. Risk of renal toxicity is significantly greater with zoledronic acid injection 8 mg compared to 4 mg.